These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 15253102

  • 1. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
    Kojima S, Shida M, Yokoyama H.
    Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
    [Abstract] [Full Text] [Related]

  • 2. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators.
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [Abstract] [Full Text] [Related]

  • 3. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H.
    Clin Exp Hypertens; 2010 Dec; 32(6):400-5. PubMed ID: 20828221
    [Abstract] [Full Text] [Related]

  • 4. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
    Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T.
    Nephron Physiol; 2005 Dec; 101(1):p1-13. PubMed ID: 15886499
    [Abstract] [Full Text] [Related]

  • 5. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T.
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [Abstract] [Full Text] [Related]

  • 6. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
    Fan YY, Kohno M, Nakano D, Ohsaki H, Kobori H, Suwarni D, Ohashi N, Hitomi H, Asanuma K, Noma T, Tomino Y, Fujita T, Nishiyama A.
    J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
    [Abstract] [Full Text] [Related]

  • 7. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.
    Hatta T, Takeda K, Shiotsu Y, Sugishita C, Adachi T, Kimura T, Sonomura K, Kusaba T, Kishimioto N, Narumiya H, Tanda S, Tamagaki K, Yamada K, Kameyama H, Kido H, Harada S, Bito Y, Moriguchi J, Morimoto S, Okigaki M, Itoh H, Mori Y, Nakata T, Maki K, Sasaki S, Sawada K, Matsubara H.
    J Int Med Res; 2012 May; 40(4):1417-28. PubMed ID: 22971493
    [Abstract] [Full Text] [Related]

  • 8. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, Wakatsuki T, Orino S, Kawano K, Sata M.
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K, Ueshima K, Tanaka S, Kosugi S, Sato T, Matsuoka H, Nakao K, Fujita T.
    Int J Med Sci; 2013 Nov; 10(9):1209-16. PubMed ID: 23935398
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
    Takei K, Araki N, Ohkubo T, Tamura N, Yamamoto T, Furuya D, Yanagisawa CT, Shimazu K.
    Intern Med; 2009 Nov; 48(16):1357-61. PubMed ID: 19687579
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records.
    Jadhav U, Mohanan PP, Almeida AF, Abraham G, Khan MY, Gaurav K, Mane A, Vikas S, Jain M, Meel B.
    Cardiol Ther; 2021 Dec; 10(2):465-480. PubMed ID: 34115326
    [Abstract] [Full Text] [Related]

  • 12. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T, Kaeriyama S, Urabe M, Nakaya T, Yamada M, Ichikawa M, Yamamoto K, Sato S, Imagawa M, Fujii M, Makino Y, Zenimaru Y, Wakahara S, Suzuki J, Ishizuka T, Nakamura H, Genomic Disease Outcome Consortium (G-DOC) Study Investigators.
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [Abstract] [Full Text] [Related]

  • 13. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M, Maruyama N, Suzuki H, Inoshita A, Yoshida Y, Okada K, Soma M.
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S, Harada E, Sugino K, Nishimura M, Nakamura T, Takahara A.
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [Abstract] [Full Text] [Related]

  • 15. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K.
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [Abstract] [Full Text] [Related]

  • 16. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
    Hwang YC, Yoon KH, Cha BS, Lee KW, Jang HC, Min KW, Chung CH, Lee MK.
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28840637
    [Abstract] [Full Text] [Related]

  • 17. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
    Shimizu H, Nakagami H, Yasumasa N, Mariana OK, Kyutoku M, Koriyama H, Nakagami F, Shimamura M, Rakugi H, Morishita R.
    Hypertens Res; 2012 Jan; 35(1):77-81. PubMed ID: 21881574
    [Abstract] [Full Text] [Related]

  • 18. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
    Uchida S, Takahashi M, Sugawara M, Saito T, Nakai K, Fujita M, Mochizuki K, Shin I, Morita T, Hikita T, Itakura H, Takahashi Y, Mizuno S, Ohno Y, Ito K, Ito T, Soma M.
    J Clin Hypertens (Greenwich); 2014 Oct; 16(10):746-53. PubMed ID: 25264215
    [Abstract] [Full Text] [Related]

  • 19. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
    Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T, Ishida Y, Suzuki H.
    Hypertens Res; 2001 Jul; 24(4):377-83. PubMed ID: 11510750
    [Abstract] [Full Text] [Related]

  • 20. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
    Ueshiba H, Miyachi Y.
    Intern Med; 2004 Jul; 43(7):561-5. PubMed ID: 15335180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.